Denali Therapeutics reports Q3 earnings beat and raises Q4 AVLAYAH revenue outlook
Denali Therapeutics posted third‑quarter 2026 net product revenue of $17.8 million, far above the $12.2 million consensus and representing a 394% sequential increase. Adjusted earnings came in at $0.37 per share, beating the expected loss of $0.37. Management guided fourth‑quarter net product revenue to $30 million‑$32 million, citing expanding payer coverage and a permanent J‑code that took effect on October 1. The company also highlighted a cash position of $1.01 billion and plans to file a BLA for a Sanfilippo program in 2027.
Why it matters
The earnings beat and raised guidance signal that AVLAYAH’s launch is exceeding expectations, which could support a higher valuation for DNLI (the company expects the product to drive continued revenue growth). The guidance increase also sets a new revenue floor for the next quarter, reducing short‑term earnings uncertainty for investors.
Key facts
- 1Q3 2026 net product revenue was $17.8 million investing.com
- 2Adjusted EPS for Q3 was $0.37 per share, versus an expected loss of $0.37 per share investing.com
- 3Management guided Q4 2026 net product revenue to $30 million‑$32 million investing.com
- 4AVLAYAH coverage expanded to more than 70% of commercial lives during the quarter finance.yahoo.com
- 5A permanent J‑code for AVLAYAH became effective on October 1, 2026 finance.yahoo.com
- 6Denali reported cash of $1.01 billion at quarter end finance.yahoo.com
Summary written by AlphAI AI Desk from 7 of 7 sources. Not investment advice. Figures are as stated by the linked sources.